{"DataElement":{"publicId":"3913862","version":"1","preferredName":"Chemotherapy Continue Administration Somatostatin Analog Therapy Yes No Indicator","preferredDefinition":"the yes/no indicator that asks whether somatostatin analogue chemotherapy is continuing while on study.","longName":"PRIOR_TX_SOMATOSTATIN_CONT","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"3913852","version":"1","preferredName":"Chemotherapy Continue Administration Somatostatin Analog Therapy","preferredDefinition":"information related to the continued administration of somatostatin analogue chemotherapy.","longName":"2404910v1.0:3913850v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2404910","version":"1","preferredName":"Chemotherapy","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0094ACAF-12DD-1BCA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-09-13","modifiedBy":"ONEDATA","dateModified":"2005-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3913850","version":"1","preferredName":"Continue Somatostatin Analog Therapy Administration","preferredDefinition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.:No Value Exists:The act of administration.","longName":"C53279:C15449:C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Continue","conceptCode":"C53279","definition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Somatostatin Analog Therapy","conceptCode":"C15449","definition":"Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7D6C80F-AA42-8701-E040-BB89AD432042","latestVersionIndicator":"Yes","beginDate":"2013-10-03","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-03","modifiedBy":"ONEDATA","dateModified":"2013-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7D6C80F-AA53-8701-E040-BB89AD432042","latestVersionIndicator":"Yes","beginDate":"2013-10-03","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"IE_IEORRES_CONCURSSA","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Is somatostatin analogue cont","type":"Preferred Question Text","description":"Is somatostatin analogue continuing while on study?","url":null,"context":"ECOG-ACRIN"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Concurrent somatostatin analog","url":null,"context":"Alliance"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Current somatostatin analog use during this reporting period","url":null,"context":"Alliance"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Concurrent Somatostatin Analog Use","url":null,"context":"Alliance"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Concurrent somatostatin analog (SSA) use","url":null,"context":"Alliance"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Are the Patient and the Investigator willing to discontinue use of SSAs if they are not being used to explicitly treat carcinoid syndrome in the event the patient is randomized to the everolimus treatment arm?","url":null,"context":"CCTG"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7D66DB8-6391-D8BA-E040-BB89AD436B36","latestVersionIndicator":"Yes","beginDate":"2013-10-03","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-03","modifiedBy":"CLOHNES","dateModified":"2022-12-21","changeDescription":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"12/21/22 added AQT and alt OID, CCTG for ticket number CADSR0001818 cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}